No matter what happens with the SCOTUS’s healthcare reform decision, UnitedHealthcare says it will continue to uphold many of the ACA measures that have already been enacted, including offering policyholders preventive services with no co-pays, allowing young adults to stay on their parents plan until age 26 and ending lifetime dollar limits. It wouldn’t, however, abide by the measure that says insurers can’t reject children because of pre-existing conditions. Although industry insiders have hinted that other insurers would keep certain provisions regardless of the Supreme Court decision, United is the first to say so publicly. Will others follow?
Johnson & Johnson will pay up to $2.2 billion to settle lawsuits over its marketing campaigns for Risperdal and other drugs, Bloomberg reports. If Bloomberg’s anonymous sources are right, this would be one of the government’s biggest settlement with a pharma, behind Pfizer’s $2.3 billion settlement in 2009.
The FDA approved Perjerta, a Genentech breast cancer drug to be used alongside Herceptin, on Friday. But Genentech is saying there might already be a shortage of the drug due to manufacturing problems.
Lessons from a 19-year-old venture capitalist. Alex Banayan tells the story of how he went from a tech-obsessed college student to a young VC associate.
What will happen to Pfizer stock post-break up? Matthew Herper explains in this Forbes piece.
Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.